Companies · Biotechnology

Precision Nanosystems Inc.

VANCOUVER · Biotechnology

Diligence memoA one-page analyst read on Precision Nanosystems Inc. — recommendation, valuation, rhythm, risks.
$22.3M
Total raised · real
3
Rounds
2.0×
Latest step-up
Top 32%
Sector rank · raised
Series A
Latest stage · inferred · Mon Aug 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Precision Nanosystems Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.60× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Precision Nanosystems Inc. is one of 4291 Biotechnology companies tracked from VANCOUVER. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
13
Investors (latest)
2019-08-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2015-09-22 Raised $7.3M (real) Modeled valuation $263M (est)$7.3M$263MSeries A2015Series A · 2015-09-22 Raised $13M (real) Modeled valuation $485M (est)$13M$485MSeries A2015Series A · 2018-05-17 Raised $5.9M (real) Modeled valuation $215M (est)$5.9M$215MSeries A2018Series A · 2019-08-19 Raised $3.0M (real) Modeled valuation $108M (est)$3.0M$108MSeries A2019Series A · 2019-08-19 Raised $6.0M (real) Modeled valuation $217M (est)$6.0M$217MSeries A2019+$13M+$5.9M+$3.0M+$6.0MCumulative $36M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$7.3M · 2015
Series A extension$13.4M · 2015
Series A extension$5.9M · 2018
Series A extension$3.0M · 2019
Series A extension$6.0M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$107.7M
Base estimate est.
$3.3M
Conservative case
$585.8M
Upside case
$13.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $263.4M · 2015-09-222015Series A · modeled $484.5M · 2015-09-22Series A · modeled $214.8M · 2018-05-17Series A · modeled $107.7M · 2019-08-19Series A · modeled $216.9M · 2019-08-192019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
6.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$5.7M/yr
Capital velocity
10.8 yr
On record since
2015
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.1× above median
This company$22.3M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.1× above median
This company$6.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.7× above median
This company$107.7M
Sector median$64.2M

Raised more than 69% of sector peers (real $). Modeled value above 60% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #159 of 216.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $541.9M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $484.6M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Precision Nanosystems Inc. (this company) Raised $22.3M · modeled $107.7M (est)Precision Nanosystems Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$541.9M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Taiga Biotechnologies, Inc.Series A$37.9M$484.6M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Precision Nanosystems Inc. this companySeries A$22.3M$107.7M0.60×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$7.3M2015-09-22$33.1M$263.4M85%
Series A$13.4M2015-09-22$60.9M$484.5M90%
Series A$5.9M2018-05-17$27.0M$214.8M90%
Series A$3.0M2019-08-19$13.5M$107.7M90%
Series A$6.0M2019-08-19$27.3M$216.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$7.3M2015-09-22
    • First recorded raise — entered as Series A.
    • 7 investors on this round.
  2. Series A$13.4M2015-09-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× larger than the prior — scaling up.
    • 7 investors on this round.
  3. Series A$5.9M2018-05-17
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 8 investors on this round.
  4. Series A$3.0M2019-08-19
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  5. Series A$6.0M2019-08-19
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
    • 13 investors on this round.
Intelligence
2020 ~Q3
Modeled next raise · ~12mo cadence
$12.1M
Modeled next size est.range $7.9M$19.3M
2.0×
Last step-up
$5.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Andrew J. Schwab6 other2015-09
Andrew Clark Booth2019-08
Andrew James Booth2015-09
Daniel Clark Nixon2019-08
Daniel James Nixon2015-09
Deval Clark Lashkari2019-08
Deval James Lashkari2015-09
Euan Clark Ramsay2019-08
Euan James Ramsay2015-09
Joe Clark Victor2019-08
Joe James Victor2015-09
Mira Clark Chaurushiya2019-08
R. James Taylor2015-09
Robert James Taylor2019-08
Steve Clark Reichenbach2019-08
Registry & provenance

Precision Nanosystems Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1654441
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
DVS Sciences, Inc.BiotechnologySeries A$4.1M$149.4Mnetwork1 shared operator · same sector · same stage
76Bio, Inc.BiotechnologySeries A$22.2M$125.9Msame sector · same stage
Earth Renewable Technologies, Inc.BiotechnologySeries A$22.7M$118.2Msame sector · same stage
Akston Biosciences CorpBiotechnologySeries A$21.7M$82.6Msame sector · same stage
Micromed Cardiovascular IncBiotechnologySeries A$23.0M$115.2Msame sector · same stage
UCAN CoBiotechnologySeries A$21.5M$119.7Msame sector · same stage
Isto Technologies IncBiotechnologySeries A$21.1M$88.9Msame sector · same stage
Medicenna Therapeutics Corp.BiotechnologySeries A$23.8M$82.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Precision Biosciences IncBiotechnologySeries C$1.6B94%
Precise Bio, Inc.BiotechnologySeries B$198.8M93%
Precision Epigenomics IncBiotechnologySeed$739K91%
Integrated Nano-Technologies, Inc.BiotechnologySeries A$227.8M90%
NanoTomer, Inc.BiotechnologyPre-Seed$52.4M89%
Precision IBD, Inc.BiotechnologySeries C$1.8B88%
Nanotech Energy, Inc.BiotechnologySeries B$1.1B87%
NanoTouch Materials, LLCBiotechnologyPre-Seed$33.1M87%
Frequently asked
How much funding has Precision Nanosystems Inc. raised?
Precision Nanosystems Inc. has raised approximately $22.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Precision Nanosystems Inc.'s estimated valuation?
Provath's modeled valuation for Precision Nanosystems Inc. is approximately $107.7M (modeled range $3.3M–$585.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Precision Nanosystems Inc. at?
Precision Nanosystems Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Aug 19.
What does Precision Nanosystems Inc. do and where is it based?
Precision Nanosystems Inc. operates in the Biotechnology sector, based in VANCOUVER.
Explore related

See where Precision Nanosystems Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Precision Nanosystems Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.